Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study) (ESPIRA)
Primary Purpose
Allergic Asthma
Status
Completed
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
IgE adsorber
Sponsored by

About this trial
This is an interventional treatment trial for Allergic Asthma focused on measuring asthma, bronchial, immunoadsorbents, apheresis, immunoglobulin E
Eligibility Criteria
Inclusion Criteria:
- Signed Informed Consent
- Clinically relevant allergy to respiratory allergens confirmed by patient's history, skin-prick testing, IgE serology
- Allergic asthma (diagnosed by lung specialist)
- IgE concentration in blood at least 300 kilo Units (kU)/L
Exclusion Criteria:
- Participation in another trial within 30 days prior to enrolment
- Gravidity (pregnancy test prior to each treatment cycle)
- Intake of omalizumab
- Hepatitis or HIV or malignant disease
- Specific immunotherapy in the last 6 months
- Non-allergic asthma
- Auto-immune diseases
- Hypocalcaemia
- Intake of ACE-inhibitors (discontinuation according to half-time before treatment possible)
- Uncontrolled bleeding and coagulation disorders
- Severe cardiovascular disease
- Severe cardiac arrhythmias
- Severe systemic infection
- Unability to tolerate therapeutic apheresis procedures (hypersensitivity associated with previous apheresis sessions)
- Inadequate peripheral venous access
- Condition in which acute fluid shifts may cause congestive heart failure
- Established or suspected intra-cranial disease where fluid imbalance or pressure changes could exacerbate the disease
- Impaired renal function
- Clinically significant hypotension or borderline hypotension where a further drop in blood pressure could be harmful
Sites / Locations
- Medical University Vienna
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
apheresis, IgE adsorber
Conventional drug treatment
Arm Description
9 apheresis treatments with the new IgE adsorber in a period of 3 months with 3 cycles of 3 treatments each every month.
Patients treated with conventional asthma treatment as prescribed before study entry. No intervention in prescription
Outcomes
Primary Outcome Measures
Reduction of IgE concentration in Plasma/Serum
Decrease in IgE concentrations from before the first apheresis treatment (in the control group the first blood sampling) to after the last apheresis treatment after three months (in the control group last blood sampling after three months)
Secondary Outcome Measures
Full Information
NCT ID
NCT02096237
First Posted
March 21, 2014
Last Updated
March 5, 2015
Sponsor
Fresenius Medical Care Deutschland GmbH
1. Study Identification
Unique Protocol Identification Number
NCT02096237
Brief Title
Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study)
Acronym
ESPIRA
Official Title
First in Man Trial to Investigate Safety and Efficacy of the New IgE Adsorber
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
December 2013 (undefined)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
November 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fresenius Medical Care Deutschland GmbH
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this study patients suffering from Immunoglobulin E (IgE) mediated asthma are treated with a method, called immune apheresis, that removes IgE from blood. In order to achieve this blood is taken continuously from the patient and then separated into plasma and blood cells by centrifuge. The plasma passes the new IgE adsorber where the IgE is specifically bound. The "cleaned" plasma re-joined with the blood cells is given back to the patient. In total each patient randomized to the apheresis group will undergo 3 treatments per week (i.e. 1 cycle) every 4 weeks over a time period of 3 months, that means 9 apheresis treatments in 3 cycles in total. Study hypothesis is that the new IgE adsorber is capable of reducing IgE in plasma/serum by at least 50% measured before the first treatment in the first cycle and after the last treatment in the last treatment cycle. The new adsorber can be safely used in patients. A group of patients with conventional drug treatment and no apheresis treatment serves as control.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Allergic Asthma
Keywords
asthma, bronchial, immunoadsorbents, apheresis, immunoglobulin E
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
14 (Actual)
8. Arms, Groups, and Interventions
Arm Title
apheresis, IgE adsorber
Arm Type
Experimental
Arm Description
9 apheresis treatments with the new IgE adsorber in a period of 3 months with 3 cycles of 3 treatments each every month.
Arm Title
Conventional drug treatment
Arm Type
No Intervention
Arm Description
Patients treated with conventional asthma treatment as prescribed before study entry. No intervention in prescription
Intervention Type
Device
Intervention Name(s)
IgE adsorber
Intervention Description
Two plasma volumes of each patient in the apheresis group will be treated per session
Primary Outcome Measure Information:
Title
Reduction of IgE concentration in Plasma/Serum
Description
Decrease in IgE concentrations from before the first apheresis treatment (in the control group the first blood sampling) to after the last apheresis treatment after three months (in the control group last blood sampling after three months)
Time Frame
Before first treatment (baseline) to after the last of 9 treatments over a time period of 3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signed Informed Consent
Clinically relevant allergy to respiratory allergens confirmed by patient's history, skin-prick testing, IgE serology
Allergic asthma (diagnosed by lung specialist)
IgE concentration in blood at least 300 kilo Units (kU)/L
Exclusion Criteria:
Participation in another trial within 30 days prior to enrolment
Gravidity (pregnancy test prior to each treatment cycle)
Intake of omalizumab
Hepatitis or HIV or malignant disease
Specific immunotherapy in the last 6 months
Non-allergic asthma
Auto-immune diseases
Hypocalcaemia
Intake of ACE-inhibitors (discontinuation according to half-time before treatment possible)
Uncontrolled bleeding and coagulation disorders
Severe cardiovascular disease
Severe cardiac arrhythmias
Severe systemic infection
Unability to tolerate therapeutic apheresis procedures (hypersensitivity associated with previous apheresis sessions)
Inadequate peripheral venous access
Condition in which acute fluid shifts may cause congestive heart failure
Established or suspected intra-cranial disease where fluid imbalance or pressure changes could exacerbate the disease
Impaired renal function
Clinically significant hypotension or borderline hypotension where a further drop in blood pressure could be harmful
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kurt Derfler, Prof. Dr.
Organizational Affiliation
Dep. of Internal Medicine III, Nephrology and Dialysis
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University Vienna
City
Vienna
ZIP/Postal Code
A-1090
Country
Austria
12. IPD Sharing Statement
Citations:
PubMed Identifier
28254561
Citation
Lupinek C, Derfler K, Lee S, Prikoszovich T, Movadat O, Wollmann E, Cornelius C, Weber M, Froschl R, Selb R, Blatt K, Smiljkovic D, Schoder V, Cervenka R, Plaichner T, Stegfellner G, Huber H, Henning R, Kozik-Jaromin J, Perkmann T, Niederberger V, Petkov V, Valent P, Gauly A, Leinenbach HP, Uhlenbusch-Koerwer I, Valenta R. Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy. EBioMedicine. 2017 Mar;17:119-133. doi: 10.1016/j.ebiom.2017.02.007. Epub 2017 Feb 12.
Results Reference
derived
Learn more about this trial
Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study)
We'll reach out to this number within 24 hrs